SNY Share Price

Open 47.53 Change Price %
High 47.57 1 Day -0.15 -0.32
Low 47.14 1 Week 0.00 0.00
Close 47.28 1 Month -2.21 -4.47
Volume 1099730 1 Year 6.24 15.20
52 Week High 50.65
52 Week Low 38.45
SNY Important Levels
Resistance 2 47.68
Resistance 1 47.51
Pivot 47.33
Support 1 47.05
Support 2 46.88
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
RAI 65.40 -2.23%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TREX 109.45 25.65%
HZO 18.55 22.04%
SSD 55.74 14.62%
TBI 27.10 14.11%
SSTK 38.99 13.84%
KAI 113.60 13.09%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Sanofi (NYSE: SNY)

SNY Technical Analysis 2
As on 31st Oct 2017 SNY Share Price closed @ 47.28 and we RECOMMEND Buy for LONG-TERM with Stoploss of 45.88 & Strong Sell for SHORT-TERM with Stoploss of 49.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
SNY Target for November
1st Target up-side 49.19
2nd Target up-side 50.52
3rd Target up-side 51.86
1st Target down-side 45.37
2nd Target down-side 44.04
3rd Target down-side 42.7
SNY Other Details
Segment EQ
Market Capital 99999997952.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.sanofi-aventis.com
SNY Address
SNY
54, Rue La Bo
Paris, 75008
France
Phone: 33 1 53 77 40 00
SNY Latest News
Interactive Technical Analysis Chart Sanofi ( SNY NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sanofi
SNY Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.